PLK4 inhibition: a new therapeutic for AML
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
Carboxylic nanodiamonds could be a therapeutic agent for cancer, as melanoma cells treated with them showed little to no metastasis.
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
New imaging technology called fluorescence lifetime (FLT) imaging improves the accuracy of cancer surgery for multiple tumour types.
Findings from using a 3D hydrogel to study how cancer cells physically tear the basement membrane offers promise for targeted treatment.
Mammary organoid cultures show the effects of BRCA2 mutations on breast tissue cells, increasing the likelihood of early, targeted treatment.
Research into how the amino acid arginine drives metabolic reprogramming offers promise for liver cancer treatment.